BioShares Biotechnology Products ETF (BBP)
| Assets | $26.06M |
| NAV | $52.13 |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 500,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Dec 20, 2017 |
| 1-Year Return | - |
| Volume | 263 |
| Open | 52.43 |
| Previous Close | 53.11 |
| Day's Range | 52.13 - 53.11 |
| 52-Week Low | 46.16 |
| 52-Week High | 61.39 |
| Beta | 1.00 |
| Holdings | 54 |
| Inception Date | Dec 17, 2014 |
About BBP
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.
Top 10 Holdings
26.94% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna | MRNA | 4.19% |
| Travere Therapeutics | TVTX | 3.09% |
| BioNTech SE | BNTX | 3.06% |
| Biohaven Pharmaceutical | BHVN | 2.58% |
| Blueprint Medicines | BPMC | 2.42% |
| ADC Therapeutics SA | ADCT | 2.39% |
| Acceleron Pharma | XLRN | 2.33% |
| Regeneron Pharmaceuticals | REGN | 2.33% |
| Harmony Biosciences | HRMY | 2.30% |
| Bny Mellon Cash Reserve Usd | N/A | 2.25% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2017 | $0.0723 | Dec 27, 2017 |
| Dec 21, 2015 | $0.39725 | Dec 29, 2015 |
News
Beyond Clean Energy, 5 Sector ETFs Soaring to Record Highs
As most corners of the market rallied on the slew of positive news, a few sectors scaled new highs. We have highlighted five ETFs from different sectors that hit all-time highs in the recent trading ses...
4 ETFs to Play the Hot Events of Q4
The S&P 500 posted its best third-quarter gains since 2010 with an advancement of 8.5%. The gains could continue as the October-December period is normally gainful for the market.
Top-Performing ETFs of the Worst September Since 2011
After a superb August, September turned gloomy for Wall Street.
5 ETFs Shining Bright Amid September Selling
The combination of lofty valuation, lack of additional fiscal stimulus package, election uncertainty and rising U.S.-China tensions weighed on investors' sentiment.
"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs
After a superb August, September looks gloomy for Wall Street. Still,
Biotech ETFs Surge on a Flurry of Positive News
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
ACADIA Pharmaceuticals Help Lift Biotech ETFs
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS: A...
Biotechnology Market on a Tear: 5 ETFs in Spotlight
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
